Dissidents Win Some, Lose Some In Amylin Showdown
This article was originally published in The Pink Sheet Daily
Shareholder vote rocks the Amylin boat, but only very gently.
You may also be interested in...
The money raised will bring the San Diego company’s total to $43 million and will be used to advance its delayed-release metformin, NewMet, through Phase IIb and into a partnership. The cash also will fund an efficacy trial for over-the-counter dietary supplement Lovidia.
Amgen’s decision to take exclusive license to CK-1827452 triggers a $50 million license fee to Cytokinetics.
Label with expanded language about thyroid cancer risk is expected.